CDX2 and colorectal adenocarcinoma: Based on the studies mentioned above CDX2 expression alone does not reliably distinguish between colorectal adenocarcinomas and adenocarcinomas arising elsewhere in the GI tract, particularly pancreatobiliary and gastric adenocarcinomas, although the sensitivityof CDX2 for colorectal cancer is significantly higher than for these latter tumors.